Skip to main content
Premium Trial:

Request an Annual Quote

Richard Bender, Mark Day, Tara Hennen

Premium
Agendia has named Richard Bender as VP and chief medical officer.
 
Bender was medical director in the oncology division of Quest Diagnostics, and he was involved in clinical oncology at Kaiser Permanente. Bender also was on the executive board of San Diego’s Hospice and the American Cancer Society and he was an instructor at the UCLA School of Medicine.
 

 
PsychoGenics has named Mark Day to be senior director of cognitive neuroscience. Day formerly was involved in developing cognitive treatments for schizophrenia and Alzheimer’s disease at Wyeth Neuroscience and at GlaxoSmithKline.
 

 
Pacific Biomarkers has named Tara Hennen, a member of the company’s science and technology group, to be manager of its Biomarker Lab Services business.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.